XML 109 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS (Details)
$ in Thousands, € in Millions
1 Months Ended 12 Months Ended
Oct. 31, 2019
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue   $ 2,419,226   $ 2,096,039 $ 1,846,275  
Impairment loss   10,538   2,050 $ (11,846)  
FIRDAPSE | Disposal Group, Disposed of by Sale, Not Discontinued Operations            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Royalties on net product sales, minimum           7.00%
Royalties on net product sales, maximum           10.00%
Exclusive Licensing Agreement for Tralesinidase Alfa            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue $ 3,000          
Investment in equity       $ 12,600    
Exclusive Licensing Agreement for Tralesinidase Alfa | Variable Interest Entity, Not Primary Beneficiary            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Minority equity ownership 15.00%          
A&R Kuvan Agreement | Merck Serono | Maximum            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Business acquisition contingent consideration potential cash payments upon achievement of sales milestone | €     € 60.0      
Pegvaliase Agreement | Merck Serono            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Business acquisition, cash paid | €     € 125.0      
Research and Collaboration Agreement With Third Party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Impairment loss   $ 11,900